Nalador (Sulprostone)

Sulprostone mimics prostaglandin E2 and activates EP receptors on uterine smooth‑muscle and gastric cells. This triggers calcium‑mediated contraction of the uterus and stimulates mucus and bicarbonate secretion in the stomach, supporting hemostasis and mucosal protection.

The dose of Nalador is determined by the prescribing clinician based on the specific indication, patient condition, and local guidelines. Healthcare professionals calculate the appropriate infusion rate and duration for each individual case.

Nalador is intended for use during labor and the immediate postpartum period, so its safety profile is evaluated for those specific situations. It is not recommended for routine use in pregnancy before labor onset, and limited data are available for breastfeeding; clinicians should weigh benefits against potential risks.

To order Nalador, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nalador (sulprostone) is a prostaglandin E2 analog, offering a rapid onset of uterine contraction similar to oxytocin but with a distinct receptor profile. Compared with oxytocin, it may be effective when oxytocin resistance occurs, though it carries a higher risk of uterine hyperstimulation and systemic side effects.

Nalador should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability and potency.

Nalador is supplied as an intravenous solution and is administered by slow infusion through a peripheral or central venous line. The infusion rate and total dose are set by the treating physician according to the clinical indication and patient response.

Serious risks include uterine hyperstimulation leading to fetal distress, severe hypotension, bronchospasm, allergic reactions such as anaphylaxis, myocardial ischemia, and pulmonary edema. Immediate medical attention is required if any of these events occur.

Nalador is contraindicated in patients with known hypersensitivity to sulprostone or other prostaglandins, in those with uncontrolled cardiovascular disease, severe hypotension, or active severe asthma. It should also be avoided in patients where uterine hyperstimulation would pose a significant risk.